MCID: FLL014
MIFTS: 13

Fallopian Tube Transitional Cell Carcinoma

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Fallopian Tube Transitional Cell Carcinoma

MalaCards integrated aliases for Fallopian Tube Transitional Cell Carcinoma:

Name: Fallopian Tube Transitional Cell Carcinoma 12 73

Classifications:



External Ids:

Disease Ontology 12 DOID:4008
NCIt 50 C40104
UMLS 73 C1517128

Summaries for Fallopian Tube Transitional Cell Carcinoma

MalaCards based summary : Fallopian Tube Transitional Cell Carcinoma is related to transitional cell carcinoma. The drugs Bevacizumab and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include endothelial.

Related Diseases for Fallopian Tube Transitional Cell Carcinoma

Diseases related to Fallopian Tube Transitional Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 transitional cell carcinoma 10.0

Symptoms & Phenotypes for Fallopian Tube Transitional Cell Carcinoma

Drugs & Therapeutics for Fallopian Tube Transitional Cell Carcinoma

Drugs for Fallopian Tube Transitional Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 52)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 3,Phase 1 216974-75-3
2
Carboplatin Approved Phase 3,Phase 1 41575-94-4 10339178 498142 38904
3
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
4
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
5
Gemcitabine Approved Phase 3,Phase 2 95058-81-4 60750
6
Olaparib Approved Phase 3,Phase 2 763113-22-0 23725625
7
Topotecan Approved, Investigational Phase 2, Phase 3 119413-54-6, 123948-87-8 60700
8
Glutamic Acid Approved, Nutraceutical Phase 3 56-86-0 33032
9
Cediranib Investigational Phase 3,Phase 2 288383-20-0 9933475
10
Doxil Approved June 1999 Phase 3,Phase 2 31703
11
Maleic acid Experimental Phase 3,Phase 2 110-16-7 444266
12 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
13 Angiogenesis Inhibitors Phase 3,Phase 1
14 Angiogenesis Modulating Agents Phase 3,Phase 1
15 Antibodies Phase 3,Phase 2,Phase 1
16 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
17 Antimitotic Agents Phase 3,Phase 2,Phase 1
18 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
19 Endothelial Growth Factors Phase 3,Phase 1
20 Immunoglobulin G Phase 3,Phase 1
21 Immunoglobulins Phase 3,Phase 2,Phase 1
22 Mitogens Phase 3,Phase 1
23 Anti-Bacterial Agents Phase 3,Phase 2
24 Antibiotics, Antitubercular Phase 3,Phase 2
25 Anti-Infective Agents Phase 3,Phase 2
26 Antimetabolites Phase 3,Phase 2
27 Antimetabolites, Antineoplastic Phase 3,Phase 2
28 Antiviral Agents Phase 3,Phase 2
29 Immunosuppressive Agents Phase 3,Phase 2
30 Poly(ADP-ribose) Polymerase Inhibitors Phase 3,Phase 2,Phase 1
31 Protein Kinase Inhibitors Phase 3,Phase 2
32 Topoisomerase Inhibitors Phase 3,Phase 2
33 Carotenoids Phase 3
34 Micronutrients Phase 3,Not Applicable
35 Trace Elements Phase 3,Not Applicable
36 topoisomerase I inhibitors Phase 2, Phase 3
37 taxane Phase 3
38
Iodine Approved, Investigational Phase 2 7553-56-2 807
39
nivolumab Approved Phase 2 946414-94-4
40
Xylometazoline Approved, Investigational Phase 2 526-36-3 5709
41
Bortezomib Approved, Investigational Phase 1 179324-69-7 387447 93860
42
Cisplatin Approved Phase 1 15663-27-1 84093 441203 2767
43
Veliparib Investigational Phase 1 912444-00-9 11960529
44
Folic Acid Approved, Nutraceutical, Vet_approved Not Applicable 59-30-3 6037
45
leucovorin Approved, Nutraceutical Not Applicable 58-05-9 143 6006
46 Hematinics Not Applicable
47 Vaccines Not Applicable
48 Vitamin B Complex Not Applicable
49 Vitamins Not Applicable
50 CHI3L1 protein, human

Interventional clinical trials:

(show all 14)
# Name Status NCT ID Phase Drugs
1 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
2 Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02446600 Phase 3 Carboplatin;Cediranib Maleate;Gemcitabine Hydrochloride;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride
3 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
4 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
5 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
6 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Suspended NCT02502266 Phase 2, Phase 3 Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
7 MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer Recruiting NCT02364713 Phase 2 Gemcitabine Hydrochloride;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
8 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
9 Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00888615 Phase 2 Elesclomol Sodium;Paclitaxel
10 Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT01074411 Phase 1 Bortezomib;Carboplatin
11 Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT00989651 Phase 1 Carboplatin;Cisplatin;Paclitaxel;Veliparib
12 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers Suspended NCT02020707 Phase 1 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
13 Vaccine Therapy in Treating Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Following Surgery and Chemotherapy Active, not recruiting NCT02111941 Not Applicable
14 YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy Terminated NCT00899093

Search NIH Clinical Center for Fallopian Tube Transitional Cell Carcinoma

Genetic Tests for Fallopian Tube Transitional Cell Carcinoma

Anatomical Context for Fallopian Tube Transitional Cell Carcinoma

MalaCards organs/tissues related to Fallopian Tube Transitional Cell Carcinoma:

41
Endothelial

Publications for Fallopian Tube Transitional Cell Carcinoma

Articles related to Fallopian Tube Transitional Cell Carcinoma:

# Title Authors Year
1
Primary fallopian tube transitional cell carcinoma. ( 25162143 )
2014

Variations for Fallopian Tube Transitional Cell Carcinoma

Expression for Fallopian Tube Transitional Cell Carcinoma

Search GEO for disease gene expression data for Fallopian Tube Transitional Cell Carcinoma.

Pathways for Fallopian Tube Transitional Cell Carcinoma

GO Terms for Fallopian Tube Transitional Cell Carcinoma

Sources for Fallopian Tube Transitional Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....